Earnings ·
Acadia Pharmaceuticals reported second quarter 2026 financial results, posting GAAP total revenues of $308 million, a…
ACADAcadia Pharmaceuticals Inc
Acadia Pharmaceuticals reported second quarter 2026 financial results, posting GAAP total revenues of $308 million, a 17% increase from the prior year period. Net income was $32 million, or $0.18 per diluted share, compared to $27 million in Q2 2025. NUPLAZID net sales reached $183 million, up 9% year-over-year, while DAYBUE net sales grew 30% to $125 million. The company raised its full-year 2026 total revenue guidance to a range of $1.24 to $1.30 billion from the previous estimate of $1.22 to $1.28 billion. Additionally, Acadia received FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis and announced that EMA CHMP adopted a positive opinion recommending marketing authorization for DAYBUE in Rett syndrome. The company operates in the pharmaceutical industry, developing and commercializing treatments for neurological and rare diseases.